Price
No data yet.
Social Signal Score
Analyst Ratings
43 analystsRevenue
$11.99B+167.07%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Marc N. Casper
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- Employees
- 125,000
- Beta
- 0.85
- Country
- US
- Piotroski score
- 6 / 9 (Middling)
- Altman Z-score
- 3.92
Financials
Revenue
$11.99B+167.1%Net Income
$1.74B+266.6%EBITDA
$2.57B+164.0%Free Cash Flow
$1.68B+142.5%EPS (diluted)
$4.68+293.3%Shares Outstanding (diluted)
371.00M-6.6%Operating Expenses
$2.27BCash & Debt
$4.06BReturn of Capital
$1.18BRevenue by Segment (annual)
$44.56BDividend per Share
$0.47Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $44.56B | $6.74B | $17.77 |
| 2024 | $42.88B | $6.33B | $16.58 |
| 2023 | $42.86B | $6.00B | $15.53 |
| 2022 | $44.91B | $6.95B | $17.73 |
| 2021 | $39.21B | $7.72B | $19.61 |
| 2020 | $32.22B | $6.38B | $16.10 |
| 2019 | $25.54B | $3.70B | $9.24 |
| 2018 | $24.36B | $2.94B | $7.31 |
| 2017 | $20.92B | $2.23B | $5.64 |
| 2016 | $18.27B | $2.02B | $5.12 |
| 2015 | $16.97B | $1.98B | $4.96 |
| 2014 | $16.89B | $1.89B | $4.76 |
| 2013 | $13.09B | $1.27B | $3.53 |
| 2012 | $12.51B | $1.18B | $3.24 |
Valuation
Project earnings forward and see what return today's price implies.
Seeded from TMO's reported EPS growth of 14.0% a year over 13 years.
- EPS in 5 years
- $34.50
- Implied price
- $1,138
- Return from $669.43
- 11.2% a year
To earn 15.0% a year on these assumptions you'd need to buy at $566.01 — -15.4% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 23 | 28 | 33 | 38 | 43 |
|---|---|---|---|---|---|
| 4.0% | -5.6% | -1.8% | 1.4% | 4.4% | 7.0% |
| 9.0% | -1.1% | 2.9% | 6.3% | 9.4% | 12.1% |
| 14.0% | 3.5% | 7.6% | 11.2% | 14.4% | 17.3% |
| 19.0% | 8.0% | 12.3% | 16.1% | 19.4% | 22.4% |
| 24.0% | 12.5% | 17.0% | 21.0% | 24.4% | 27.5% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
83+66.67%Social Signal Score
Mentions (21)
- Newsglobenewswire.com·8d ago·Neutral
Magnetic Beads - Global Strategic Business Report: Capitalize on the Surge from $3.3 Billion in 2025 to $7.4 Billion by 2032 as Thermo Fisher Scientific, Merck KGaA, QIAGEN, Bio-Rad Laboratories and Miltenyi Biotec Battle for Leadership Dublin, Sept. 28, 2026 (GLOBE NEWSWIRE) -- "Magnetic Beads - Global Strategic Business Report" has been added to ResearchAndMarkets. com's offering. The global magnetic beads market was valued at an estimated US$3. 3 billion in 2025 and is projected to reach US$7…
View source ↗ - Newsglobenewswire.com·8d ago·Neutral
…bal Grignard Reagents Market Outlook and Forecast, 2026–2032 - Market to Reach USD 7.87 Billion as Safer, AI-Enabled Production Expands Opportunities for Merck KGaA, Thermo Fisher Scientific, and Tokyo Chemical Industry Dublin, Sept. 28, 2026 (GLOBE NEWSWIRE) -- "Grignard Reagents Market - Global Forecast 2026-2032" has been added to ResearchAndMarkets. com's offering. The Grignard Reagents Market research report provides a comprehensive assessment of industry growth, production trends, applicat…
View source ↗ - 4chan /biz/biz·12d ago·Neutral
>>62720893 TMO, Fisher Price, etc
View source ↗ - News (RSS)yahoo·17d ago·Neutral
Thermo Fisher Scientific (TMO) is Positioned for Resurgence
View source ↗ - News (RSS)yahoo·19d ago·Positive
Thermo Fisher Sees Stronger Demand, Calls 2026 an ‘Outstanding Year’
View source ↗ - Newsmarketbeat.com·19d ago·Positive
Thermo Fisher Sees Stronger Demand, Calls 2026 an ‘Outstanding Year' Thermo Fisher Scientific NYSE: TMO Chairman and Chief Executive Officer Marc Casper said the company is seeing improving demand across several end markets and expects 2026 to be an “outstanding year,” supported by stronger customer activity and operational execution.
View source ↗ - News (RSS)investing·19d ago·Neutral
Thermo Fisher Scientific stock hits 52-week high at 647.72 USD
View source ↗ - Newsseekingalpha.com·20d ago·Positive
Thermo Fisher Scientific Inc. (TMO) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript Thermo Fisher Scientific Inc. (TMO) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
View source ↗ - News (Marketaux)acquirersmultiple.com·22d ago·Positive
Jeremy Grantham’s Latest Portfolio: Top 10 Holdings & Biggest Trades Top 10 Holdings & Weights Microsoft Cor[+371 characters]
View source ↗ - News (Marketaux)thehindubusinessline.com·27d ago·Positive
HCLTech launches ₹185 cr advanced semiconductor lab in Bengaluru The facility is equipped with tools from[+312 characters]
View source ↗ - News (RSS)ft·29d ago·Neutral
Thermo Fisher CEO: ‘Society broadly embraces the breakthroughs’ Pandemic thrust US biotech and Marc Casper on to the world stage
View source ↗ - Newszacks.com·31d ago·Neutral
Should You Continue to Hold TMO Stock in Your Portfolio? Thermo Fisher's growth is gaining momentum as acquisitions strengthen its life sciences reach, but macro risks and competition remain concerns.
View source ↗ - Newszacks.com·34d ago·Neutral
TMO Stock Could Gain Following the Launch of EMPAD G2 Detector Thermo Fisher's EMPAD G2 detector enhances 4D STEM imaging speed, sensitivity and workflow integration, strengthening its Analytical Instruments portfolio.
View source ↗ - News (RSS)yahoo·43d ago·Neutral
Medtronic vs. Thermo Fisher: Which Healthcare Turnaround Offers More Upside?
View source ↗ - News (RSS)yahoo·43d ago·Neutral
Abbott vs. Thermo Fisher: Which is the Better Investment, Diversification or Recovery?
View source ↗ - News (RSS)yahoo·43d ago·Neutral
Johnson & Johnson vs. Thermo Fisher: Which Healthcare Growth Story Is More Durable?
View source ↗ - News (RSS)yahoo·43d ago·Neutral
Thermo Fisher vs. Intuitive Surgical: Which Premium Healthcare Stock Deserves its Valuation?
View source ↗ - News (RSS)yahoo·49d ago·Neutral
Thermo Fisher Scientific Stock: Analyst Estimates & Ratings
View source ↗ - News (RSS)seekingalpha·51d ago·Positive
Thermo Fisher Scientific: Biopharma Recovery And Share Gains Support The Upside
View source ↗ - Newsseekingalpha.com·51d ago·Positive
…ry And Share Gains Support The Upside Thermo Fisher Scientific is rated a Buy, supported by accelerating organic growth and improving Pharma and Biotech end markets. TMO's recent acquisitions of Clario and Solventum's Filtration and Separation business expand capabilities, enabling greater share of customer spending and revenue synergies. Q2 2026 results showed 10% revenue growth, 5% organic growth, and improved margins, with Pharma and Biotech driving mid-single-digit gains.
View source ↗ - Newsreuters.com·57d ago·Neutral
Thermo Fisher eyes 15%-20% India customer growth on biopharma research, manufacturing boost Thermo Fisher Scientific is eyeing a 15%-20% increase in its customer base in India over the next five years, betting on the growing biopharma research and manufacturing ecosystem, the head of its India unit said.
View source ↗
Earnings
Wed, Oct 21(in 2 weeks)
Consensus estimate $6.41 per share
Typical surprise +2.7% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Jul 23$6.03 vs $5.72beat
- Thu, Apr 23$5.44 vs $5.25beat
- Thu, Jan 29$6.57 vs $6.45beat
- Wed, Oct 22$5.79 vs $5.50beat
- Wed, Jul 23$5.36 vs $5.23beat
- Wed, Apr 23$5.15 vs $5.10beat
Estimates and results for TMO via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by TMO officers and directors.
- Bought
- —
- Sold
- $37.1m
0 trades
50 trades
- Pettiti Gianlucasold
- Casper Marc Nsold
- Casper Marc Nsold
- Casper Marc Nsold
- Casper Marc Nsold
- Casper Marc Nsold
- Casper Marc Nsold
- Casper Marc Nsold
50 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
- Ro Khannahouse · CA17 · disclosed Sep 7, 2026 (31d later)Buy$1,001 - $15,000
- Michael A. Rullihouse · disclosed Aug 10, 2026 (606d later)Sell$1,001 - $15,000
- Alan Armstrongsenate · disclosed Jul 21, 2026 (116d later)Buy$1,001 - $15,000
- Daniel Milton Newhousehouse · WA04 · disclosed Jul 20, 2026 (10d later)Sell$1,001 - $15,000
- Dwight Evanshouse · PA03 · disclosed May 15, 2026 (8d later)Sell$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed May 13, 2026 (30d later)Buy$15,001 - $50,000
- Ro Khannahouse · CA17 · disclosed Apr 9, 2026 (34d later)Buy$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Feb 10, 2026 (12d later)Sell$15,001 - $50,000
- Julia Letlowhouse · LA05 · disclosed Jan 13, 2026 (172d later)Buy$1,001 - $15,000
- Julia Letlowhouse · LA05 · disclosed Jan 13, 2026 (260d later)Sell$1,001 - $15,000
- Julia Letlowhouse · LA05 · disclosed Jan 13, 2026 (447d later)Buy$1,001 - $15,000
- Lisa C. McClainhouse · MI09 · disclosed Nov 24, 2025 (24d later)Sell$1,001 - $15,000
- Lisa C. McClainhouse · MI09 · disclosed Nov 24, 2025 (25d later)Buy$1,001 - $15,000
- Lisa C. McClainhouse · MI09 · disclosed Nov 24, 2025 (25d later)Sell$1,001 - $15,000
- Val Hoylehouse · OR04 · disclosed Oct 10, 2025 (17d later)Sell$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Oct 3, 2025 (21d later)Buy$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Oct 3, 2025 (4d later)Buy$1,001 - $15,000
- Val Hoylehouse · OR04 · disclosed Sep 12, 2025 (318d later)Buy$1,001 - $15,000
- Val Hoylehouse · OR04 · disclosed Sep 12, 2025 (98d later)Buy$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Sep 12, 2025 (37d later)Buy$1,001 - $15,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.